Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Islatravir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck's Doravirine/Islatravir NDA Accepted by FDA
    Merck's Doravirine/Islatravir NDA Accepted by FDA

    10 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250710518672/en/U.S.-FDA-Accepts-New-Drug-Application-for-Mercks-DoravirineIslatravir-an-Investigational-Once-Daily-Oral-Two-Drug-Regimen-for-Treatment-of-Adults-with-Virologically-Suppressed-HIV-1-Infection

    BUSINESSWIRE
    10 Jul 2025
    Share Share
    Merck to Unveil Hiv Prevention, Treatment Data at IAS 2025
    Merck to Unveil Hiv Prevention, Treatment Data at IAS 2025

    09 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/merck-to-present-new-research-data-across-its-hiv-prevention-and-treatment-pipeline-at-ias-2025-17375

    INDPHARMAPOST
    09 Jul 2025
    Share Share
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312706063/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials

    20 Dec 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/mercks-hiv-combo-treatment-meets-bar-viral-suppression-pair-phase-3-studies

    FIERCE BIOTECH
    20 Dec 2024
    Share Share
    Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
    Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks

    22 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-gilead-long-acting-oral-combo-suppresses-hiv-48-weeks-setting-stage-pivotal-program

    FIERCE BIOTECH
    22 Oct 2024
    Share Share
    Merck-Gilead's weekly HIV combo maintains viral suppression
    Merck-Gilead's weekly HIV combo maintains viral suppression

    07 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-gileads-weekly-hiv-combo-maintains-viral-suppression-its-early-days-primary-endpoint

    FIERCE BIOTECH
    07 Mar 2024
    Share Share